Cepheid Launches TB Test under CE IVD Directive
April 27, 2009
Cepheid Launches TB Test under CE IVD Directive
The test simultaneously identifies Mycobacterium tuberculosis and resistance to first-line drug therapy rifampicin.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Q&A: Johns Hopkins' David Dowdy on a Comparative Effectiveness Study of Cepheid's Xpert TB Test
May 30, 2013 / PCR Insider - Dx Focus: PEPFAR Funding Drives Cepheid TB Test Uptake; Curetis Starts US Trials for MDx System
December 6, 2012 / PCR Insider - Cepheid Inks First in Series of Agreements to Buy Down Price of Xpert TB Test
August 9, 2012 / PCR Insider - Unitaid Provides $30M to Reduce Cost, Increase Uptake of Cepheid TB Test in Developing World
June 14, 2012 / PCR Insider - Unitaid Provides $30M to Lower Cost of Cepheid TB Test in Developing World
June 14, 2012 / GenomeWeb Daily News